BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, including the following three lead indications: Dupuytren's disease; Peyronie's disease; and Frozen Shoulder (adhesive capsulitis).

Its strategic partner Auxilium Pharmaceuticals, Inc. currently has a Biologics License Application (BLA) under priority review with the U.S. Food and Drug Administration to market XIAFLEX™ in the U.S. for the treatment of Dupuytren's disease. On September 16, 2009, the Arthritis Advisory Committee, appointed by the FDA, unanimously recommended, by a vote of 12 to 0, that the FDA approve XIAFLEX^TM for the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for commercialization of XIAFLEX™ for the treatment of Dupuytren's disease and Peyronie's disease in Europe and other territories.